Media
Home
Media
- Press
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALDLeriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective ...09/01/2020
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s AtaxiaLeriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and ...13/11/2019
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s AtaxiaLeriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and ...17/10/2019Read more